Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults

NCT05171946 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Safety
Vaccine Reaction
Vaccine Adverse Reaction
Immunization; Infection

Interventions

DRUG: S.opt.FL COVID-19 pDNA vaccine
DRUG: S.opt.FL COVID-19 pDNA vaccine
DRUG: S.opt.FL COVID-19 pDNA vaccine

Sponsor

Iman Almansour

Collaborators

[object Object]